Intra Cellular Therapies Inc Revenue Growth Rates (ITCI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intra cellular Therapies Inc   (NASDAQ: ITCI)
 

ITCI's Revenue Growth by Quarter and Year

Intra Cellular Therapies Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ITCI Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 199.22
3rd Quarter September 175.38
2nd Quarter June 161.39
1st Quarter March 144.87
FY 680.86

ITCIs Annual Revenue
Intra Cellular Therapies Inc 's Revenue in the fiscal year 2024 $ 680.85 millions
Intra Cellular Therapies Inc 's Revenue in the fiscal year 2023 $ 464.37 millions
Intra Cellular Therapies Inc 's Revenue in the fiscal year 2022 $ 250.31 millions
Intra Cellular Therapies Inc 's Revenue in the fiscal year 2021 $ 83.80 millions
Intra Cellular Therapies Inc 's Revenue in the fiscal year 2020 $ 22.81 millions




ITCI Revenue fourth quarter 2024 Y/Y Growth Comment
Intra cellular Therapies Inc reported Revenue rise of 50.81% year on year in the fourth quarter 2024, to $ 199.22 millions, this is lower than Intra Cellular Therapies Inc 's recent average Revenue surge of 739.21%.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue growth. While Intra Cellular Therapies Inc ' s Revenue jump of 50.81% ranks overall at the positon no. 345 in the fourth quarter 2024.


ITCI Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 50.81 % 50.34 % 242.31 % 106.18 %
3rd Quarter September 39 % 75.55 % 223.59 % 201.36 %
2nd Quarter June 45.67 % 99.33 % 177.21 % 949.74 %
1st Quarter March 52 % 172.31 % 120.4 % 1370.37 %
FY   46.62 % 85.51 % 198.68 % -

Financial Statements
Intra Cellular Therapies Inc 's fourth quarter 2024 Revenue $ 199.22 millions ITCI's Income Statement
Intra Cellular Therapies Inc 's fourth quarter 2023 Revenue $ 132.10 millions Quarterly ITCI's Income Statement


ITCI Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December 13.6 % 4.7 % 22.26 % 15.58 %
3rd Quarter September 8.67 % 13.88 % 29.31 % 10.77 %
2nd Quarter June 11.4 % 16.24 % 58.8 % 26.26 %
1st Quarter March 9.67 % 8.47 % 36.35 % 27.55 %
FY (Year on Year)   46.62 % 85.51 % 198.68 % -


Back to ITCI Growth rate Comparisons >> Back to ITCI Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #90
Overall #345

Revenue Y/Y Growth Statistics
High Average Low
20447.19 % 739.21 % -100 %
(Sep 30 2021)   (June 30. 2015)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #90
Overall #345
Revenue Y/Y Growth Statistics
High Average Low
20447.19 % 739.21 % -100 %
(Sep 30 2021)   (June 30. 2015)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Intra Cellular Therapies Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2144.27 % 158.85 % -100 %
(Dec 31 2016)  


ITCI's IV. Quarter Q/Q Revenue Comment
Intra cellular Therapies Inc achieved in the IV. Quarter 2024 below company average Revenue rise of 13.6% quarter on quarter, to $ 199.22 millions.

IV. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 4.7% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Intra Cellular Therapies Inc 's Revenue growth quarter on quarter, overall rank is 277.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #47
Overall #277
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #47
Overall #277
Revenue Q/Q Growth Statistics
High Average Low
2144.27 % 158.85 % -100 %
(Dec 31 2016)  


ITCI's IV. Quarter Q/Q Revenue Comment
Intra cellular Therapies Inc achieved in the IV. Quarter 2024 below company average Revenue rise of 13.6% quarter on quarter, to $ 199.22 millions.

IV. Quarter 2024 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 4.7% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Intra Cellular Therapies Inc 's Revenue growth quarter on quarter, overall rank is 277.


Intra Cellular Therapies Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)
Cumulative Revenue 12 Months Ending $ 680.85 $ 613.73 $ 564.53 $ 513.93 $ 464.37
Y / Y Revenue Growth (TTM) 46.62 % 46.08 % 54.31 % 65.45 % 85.51 %
Year on Year Revenue Growth Overall Ranking # 33 # 10 # 13 # 12 # 8
Seqeuential Revenue Change (TTM) 10.94 % 8.72 % 9.84 % 10.67 % 10.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 1155 # 672 # 359 # 160 # 76


Cumulative Revenue growth Comment
Although Intra Cellular Therapies Inc 's Annual Revenue growth year on year were below company's average 148.41% , Revenue announced in the Dec 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 46.62% year on year, from 46.08% in Sep 30 2024.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 10 to 33.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 8
Overall # 33

Revenue TTM Y/Y Growth Statistics
High Average Low
577.46 %
 148.41 %
-93.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 229
S&P 500 # 1155
Cumulative Revenue growth Comment
Although Intra Cellular Therapies Inc 's Annual Revenue growth year on year were below company's average 148.41% , Revenue announced in the Dec 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 46.62% year on year, from 46.08% in Sep 30 2024.

Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 10 to 33.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 8
Overall # 33

Revenue TTM Y/Y Growth Statistics
High Average Low
577.46 %
148.41 %
-93.22 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 229
S&P 500 # 1155




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ITCI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Blueprint Medicines Corporation88.19%$ 88.190 millions
Ac Immune Sa88.19%$ 88.190 millions
Agilon Health Inc 86.69%$ 86.693 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Genfit S a 85.82%$ 85.821 millions
Harrow Inc 83.83%$ 83.829 millions
Zymeworks Inc 83.33%$ 83.333 millions
Orgenesis Inc 82.42%$ 82.424 millions
Macrogenics Inc 80.53%$ 80.532 millions
Septerna Inc 79.66%$ 79.661 millions
Avricore Health Inc 79.01%$ 79.014 millions
Ideaya Biosciences Inc 78.43%$ 78.435 millions
Argenx Se78.05%$ 78.053 millions
Beone Medicines Ltd 77.78%$ 77.776 millions
Pluri Inc 76.19%$ 76.190 millions
Immucell Corporation75.74%$ 75.741 millions
Protalix Biotherapeutics inc 73.74%$ 73.736 millions
Standard Biotools Inc 73.73%$ 73.726 millions
Rhythm Pharmaceuticals Inc 72.61%$ 72.609 millions
Genedx Holdings Corp 66.30%$ 66.298 millions
Axsome Therapeutics Inc 66.04%$ 66.037 millions
Travere Therapeutics Inc 65.98%$ 65.976 millions
Sarepta Therapeutics Inc 65.94%$ 65.938 millions
Zai Lab Limited65.68%$ 65.684 millions
Eton Pharmaceuticals Inc 62.62%$ 62.617 millions
Aprea Therapeutics Inc 61.34%$ 61.344 millions
Rigel Pharmaceuticals Inc60.92%$ 60.919 millions
Procept Biorobotics Corporation59.55%$ 59.553 millions
Adma Biologics Inc 59.06%$ 59.057 millions
C4 Therapeutics Inc 58.75%$ 58.755 millions


About Intra Cellular Therapies Inc Revenue Growth Rates (ITCI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intra cellular Therapies Inc (CIK 1567514).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-25-006993
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intra cellular Therapies Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.